Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ortho McNeil, a subsidiary of Johnson & Johnson, has changed the label on its contraceptive patch Ortho Evra after the FDA warned that it may produce a higher risk of blood clotting than using an oral contraceptive.
Subscribe to our email newsletter
According to the FDA, woman using the patch would be exposed to 60% more estrogen than those taking an oral contraceptive pill, and this increase in exposure to the hormone is likely to be associated with a higher risk of blood clot.
The hormone is delivered directly into the bloodstream when administered by the Ortho McNeil patch, whereas an oral contraceptive is first digested.
In a statement Ortho McNeil said that “Ortho Evra has been used by more than five million women and remains a safe and effective product, when used according to the product’s label. However, hormonal contraception is not suitable for all women. It is important that women speak with their healthcare professionals about what option is right for them.”